Jivan and NimbleGen Partner for Splice Array Market
News Feb 03, 2006
"Jivan is proud to offer its full product line on NimbleGen's flexible and robust microarray platform," said Dr. Subha Srinivasan, CEO of Jivan Biologics (Berkeley, CA).
"This partnership furthers our goal to become the platform-independent solution for high-throughput splice variant analysis."
Dr. Stanley Rose, President and CEO of NimbleGen Systems (Madison, WI), commented, "Our collaboration with Jivan provides yet another example of an emerging measure of genome function or activity being enabled by NimbleGen’s platform."
"This product line nicely complements our whole genome ChIP-chip, CGH, Comparative Genome Sequencing, and Expression offerings, and further expands our integrated analytical capabilities also known as High Definition Genomics."
Researchers Awarded $28M for Illuminating Druggable Genome NIH GrantsNews
Researchers receive grants as part of the NIH program focused on experimental and informatics approaches to characterize understudied proteins from three gene families: ion channels, G protein-coupled receptors (GPCRs), and protein kinases.READ MORE
No Country for Old GenesNews
Our modern world is radically different from the one we evolved in, and that creates a mismatch between the environment our genes were evolved to face, and the world those genes now encounter. A new review looks at how certain genes that benefited humans in our genetic past now predispose us to disease in old age.READ MORE
CRISPR Editing Stops HIV Virus in Infected CellsNews
Human immunodeficiency virus-1 (HIV-1) infection is a chronic disease affecting more than 35 million people worldwide. The infection can be controlled by antiretroviral therapy (ART), but there is still no complete cure. Now, a new study targeting the regulatory genes of the virus using CRISPR/Cas9 has helped block the production of the virus by infected cells.READ MORE